|
|
|
|
AAV %Full analysis must distinguish full, empty, and partial capsids, with performance influenced by sample purity, concentration, matrix, and heterogeneity. AUC provides high-resolution characterization, while SEC-MALS, mass photometry, and ddPCR offer complementary capabilities. Selecting methods based on development stage and analytical purpose enables comprehensive product-quality assessment.
|
|
|
|
|
Functional drug response data from patient-derived organoids becomes most informative when paired with multi-omics analysis, high-content imaging, and linked clinical records, connecting sensitivity and resistance profiles to molecular mechanisms and real-world patient outcomes.
|
|
|
|
|
Discover how rational plasmid engineering and promoter optimization can increase AAV productivity while reducing plasmid burden. This approach offers a streamlined path toward more efficient, scalable viral vector manufacturing and improved process performance.
|
|
|
|
|
Explore Samsung Biologics’ expanded ADC capabilities, including its integrated bioconjugation platform designed to support next-generation therapeutics. Learn how these capabilities can help streamline development and enable scalable manufacturing from early-stage programs through commercial production.
|
|
|
|
|
|
|
|
|
|
|
